AX-2026-041747
Cagrilintide · 5 mg declared · Thermo Fisher Scientific (China) Co., Ltd. · lot TFS-{CAT}-1681
- Report ID
- AX-2026-041747
- Compound
- Cagrilintide
- Compound class
- Incretin analogues and co-agonists
- Supplier
- TFS — Thermo Fisher Scientific (China) Co., Ltd.
- Batch / lot
- TFS-{CAT}-1681
- Declared label claim
- 5mg
- Laboratory
- Janoshik Analytical
- Assay date
- 11 May 2026
- Submitted
- 25 May 2026
- Quarter
- 2026-Q2
- Submitter
- w.sorensen
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 98.96 | % area | ≥ 96.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.04 | % area | ≤ 3.5 | PASS |
| Largest single impurity | RP-HPLC — open-chain (reduced disulfide, +2 Da) | 0.51 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 3961.3218 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 3961.3273 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +1.4 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 86.58 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 85.68 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 6.14 | mg | 5 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 5.261 | mg | 5 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 105.2 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.32 | % | ≤ 8.0 | PASS |
| Counter-ion (TFA) | anion-exchange ion chromatography | 8.66 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.44 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 3.03 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 16.76 | min | 16.74 ± 0.45 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.10 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 49,424 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs deamidated (+1 Da) | 1.42 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Cagrilintide — main peak | 16.76 | 4,809,763 | 98.96 | — |
| 2 | open-chain (reduced disulfide, +2 Da) | 15.55 | 24,788 | 0.51 | +2.016 |
| 3 | disulfide-scrambled isomer | 17.24 | 13,609 | 0.28 | 0.000 |
| 4 | deamidated (+1 Da) | 16.32 | 7,290 | 0.15 | +0.984 |
| 5 | cagrilintide dimer (intermolecular disulfide) | 20.20 | 2,916 | 0.06 | +3959.306 |
| 6 | des-C16 diacid (−254 Da) | 13.14 | 1,944 | 0.04 | -254.225 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 3961.3218 Da, computed from C194H310N54O61. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 6+ | 661.2276 | 661.2285 | 0.0009 | 8.1 |
| 5+ | 793.2716 | 793.2727 | 0.0011 | 53.3 |
| 4+ | 991.3377 | 991.3391 | 0.0014 | 100.0 |
| 3+ | 1321.4479 | 1321.4497 | 0.0018 | 53.7 |
| 2+ | 1981.6682 | 1981.6709 | 0.0027 | 7.6 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.32 |
| Counter-ion (TFA) | ion chromatography | 8.66 |
| Residual solvent + inorganic residue | estimated | 0.44 |
| Total peptide content | by difference | 86.58 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.90 | 98.96 | divergence +0.56 pp vs batch median |
| Total impurities (% area) | not stated | 1.04 | |
| Largest single impurity (% area) | not stated | 0.51 | |
| Water (%) | 4.5 | 4.32 | |
| Counter-ion (%) | not stated | 8.66 | |
| Peptide content (%w/w) | not stated | 86.58 | |
| Endotoxin (EU/mg) | 1.68 | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Domestic warehouse despatch → submitter (2–8 °C, 24 d) → laboratory (courier, cold pack, 5 d) → assay.
- Assay date
- 11 May 2026
- Submitted to the index
- 25 May 2026
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot TFS-{CAT}-1681 n=13
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041738 | TFS-{CAT}-1681 | Janoshik | 2026-Q2 | 99.48 | 5.18 | 103.5 | Buyer-sourced | 0 | PASS |
| AX-2026-041739 | TFS-{CAT}-1681 | Janoshik | 2026-Q2 | 99.09 | 4.66 | 98.4 | Buyer-sourced | 0 | PASS |
| AX-2026-041740 | TFS-{CAT}-1681 | Kestrel | 2026-Q2 | 99.93 | 5.15 | 104.9 | Buyer-sourced | 0 | PASS |
| AX-2026-041741 | TFS-{CAT}-1681 | Janoshik | 2026-Q2 | 99.24 | 5.16 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041742 | TFS-{CAT}-1681 | Janoshik | 2026-Q2 | 99.54 | 4.54 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041743 | TFS-{CAT}-1681 | Medutest | 2026-Q2 | 99.28 | 4.75 | 105.8 | Buyer-sourced | 0 | PASS |
| AX-2026-041744 | TFS-{CAT}-1681 | Janoshik | 2026-Q2 | 99.72 | 5.23 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041745 | TFS-{CAT}-1681 | VendorInvestigate | 2026-Q2 | 98.59 | 4.51 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-041746 | TFS-{CAT}-1681 | PeptideMeter | 2026-Q2 | 99.20 | 5.14 | 98.9 | Buyer-sourced | 0 | PASS |
| AX-2026-041748 | TFS-{CAT}-1681 | Janoshik | 2026-Q2 | 99.41 | 4.49 | 107.2 | Buyer-sourced | 0 | PASS |
| AX-2026-041749 | TFS-{CAT}-1681 | Nordanalyt | 2026-Q2 | 99.54 | 4.21 | 89.0 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041750 | TFS-{CAT}-1681 | Janoshik | 2026-Q2 | 99.34 | 4.85 | 91.7 | Buyer-sourced | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043557 | SIG | SIG-2603-6212 | Janoshik | 2026-Q2 | 98.28 | 4.41 | 99.0 | Buyer-sourced | 0 | PASS |
| AX-2026-043545 | SIG | SIG-2603-6212 | Janoshik | 2026-Q2 | 98.25 | 4.39 | — | Buyer-sourced | 0 | PASS |
| AX-2026-043550 | SIG | SIG-2603-6212 | VendorInvestigate | 2026-Q2 | 97.80 | 4.55 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042636 | SWB | SWB-2601-J7710 | Nordanalyt | 2026-Q2 | 98.96 | 4.47 | 92.7 | Buyer-sourced | 0 | PASS |
| AX-2026-041740 | TFS | TFS-{CAT}-1681 | Kestrel | 2026-Q2 | 99.93 | 5.15 | 104.9 | Buyer-sourced | 0 | PASS |
| AX-2026-041743 | TFS | TFS-{CAT}-1681 | Medutest | 2026-Q2 | 99.28 | 4.75 | 105.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042863 | GGPeps | GGPE-2603-R2320 | Medutest | 2026-Q2 | 98.13 | 6.46 | 88.7 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042148 | JEEP | JEEP-2603-E9024 | Janoshik | 2026-Q2 | 98.66 | 6.33 | — | Buyer-sourced | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041681 | CJC-1295 with DAC | TFS-{CAT}-9675 | PeptideMeter | 2026-Q3 | 98.82 | 3.67 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041766 | BPC-157 | TFS-{CAT}-1156 | Janoshik | 2026-Q3 | 99.54 | 6.34 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041682 | CJC-1295 with DAC | TFS-{CAT}-9675 | Nordanalyt | 2026-Q3 | 98.94 | 3.24 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041683 | CJC-1295 with DAC | TFS-{CAT}-9675 | Medutest | 2026-Q3 | 98.68 | 3.46 | 97.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041765 | BPC-157 | TFS-{CAT}-1156 | Janoshik | 2026-Q3 | 99.79 | 6.01 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041680 | CJC-1295 with DAC | TFS-{CAT}-9675 | Medutest | 2026-Q3 | 99.18 | 2.85 | 100.4 | Buyer-sourced | 0 | PASS |
| AX-2026-041691 | Semaglutide | TFS-{CAT}-9744 | Janoshik | 2026-Q2 | 98.31 | 6.07 | 91.4 | Buyer-sourced | 0 | PASS |
| AX-2026-041700 | SS-31 (Elamipretide) | TFS-{CAT}-1142 | Medutest | 2026-Q2 | 99.75 | 2.27 | 96.3 | Buyer-sourced | 0 | PASS |